Speakers include moderator John James, founder of Innovate Arkansas client firm Acumen Brands; Carl Tannenbaum, chief economist at Northern Trust; John Silvia, the managing director and chief economist for Wells Fargo and Kathy Deck, director of the CBER.
InterveXion Therapeutics LLC, a University of Arkansas for Medical Sciences BioVentures startup company, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.
The third-annual Southeastern Conference Symposium will focus on the role universities play in preparing students to be entrepreneurial, innovative and creative thinkers and will explore the ways universities impact the economy.
Innovate Arkansas' own Eyenalyze is one of three tech firms that announced plans Thursday to invest in downtown Conway. Eyenalyze is a Conway-based startup that provides financial and managerial tools for the restaurant industry.
UAMS BioVentures startup and IA client firm InterveXion Therapeutics has been awarded federal grants totaling $14.5 million to further develop its drug therapies that can help methamphetamine drug abusers break their addiction.